Adams sues Perrigo
This article was originally published in The Tan Sheet
Adams Respiratory Therapeutics filed suit Sept. 27 in U.S. District Court for the District of New Jersey against Perrigo, alleging infringement of Adams' '252 patent for the Mucinex line of extended-release guaifenesin products. The lawsuit responds to the private labeler's filing of a Paragraph IV certification for an ANDA for a 600 mg guaifenesin tablet, equivalent to single-ingredient Mucinex, and initiates a 30-month stay, preventing FDA from approving Perrigo's product unless a court rules against Adams or that period expires (1"The Tan Sheet" Aug. 27, 2007, p. 12)...
You may also be interested in...
Adams Respiratory Therapeutics has been hit with another patent claim challenge involving its Mucinex line as it prepares to launch line extensions for its blockbuster brand and other new products in time for the cough/cold season
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.